Pten	0	4	B-Gene_or_gene_product
signaling	5	14	O
in	15	17	O
gliomas	18	25	B-Pathological_formation
.	25	26	O

In	28	30	O
1997	31	35	O
,	35	36	O
the	37	40	O
PTEN	41	45	B-Gene_or_gene_product
gene	46	50	O
(	51	52	O
phosphatase	52	63	B-Gene_or_gene_product
and	64	67	I-Gene_or_gene_product
tensin	68	74	I-Gene_or_gene_product
homolog	75	82	I-Gene_or_gene_product
deleted	83	90	I-Gene_or_gene_product
on	91	93	I-Gene_or_gene_product
chromosome	94	104	I-Gene_or_gene_product
10	105	107	I-Gene_or_gene_product
)	107	108	O
was	109	112	O
identified	113	123	O
as	124	126	O
a	127	128	O
tumor	129	134	B-Pathological_formation
suppressor	135	145	O
gene	146	150	O
on	151	153	O
the	154	157	O
long	158	162	O
arm	163	166	O
of	167	169	O
chromosome	170	180	O
10	181	183	O
.	183	184	O

Since	185	190	O
then	191	195	O
,	195	196	O
important	197	206	O
progress	207	215	O
has	216	219	O
been	220	224	O
made	225	229	O
with	230	234	O
respect	235	242	O
to	243	245	O
the	246	249	O
understanding	250	263	O
of	264	266	O
the	267	270	O
role	271	275	O
of	276	278	O
the	279	282	O
Pten	283	287	B-Gene_or_gene_product
protein	288	295	O
in	296	298	O
the	299	302	O
normal	303	309	O
development	310	321	O
of	322	324	O
the	325	328	O
brain	329	334	B-Organ
as	335	337	O
well	338	342	O
as	343	345	O
in	346	348	O
the	349	352	O
molecular	353	362	O
pathogenesis	363	375	O
of	376	378	O
human	379	384	B-Organism
gliomas	385	392	B-Pathological_formation
.	392	393	O

This	394	398	O
review	399	405	O
summarizes	406	416	O
the	417	420	O
current	421	428	O
state	429	434	O
of	435	437	O
the	438	441	O
art	442	445	O
concerning	446	456	O
the	457	460	O
involvement	461	472	O
of	473	475	O
aberrant	476	484	O
Pten	485	489	B-Gene_or_gene_product
function	490	498	O
in	499	501	O
the	502	505	O
development	506	517	O
of	518	520	O
different	521	530	O
biologic	531	539	O
features	540	548	O
of	549	551	O
malignant	552	561	B-Pathological_formation
gliomas	562	569	I-Pathological_formation
,	569	570	O
such	571	575	O
as	576	578	O
loss	579	583	O
of	584	586	O
cell	587	591	B-Cell
-	591	592	O
cycle	592	597	O
control	598	605	O
and	606	609	O
uncontrolled	610	622	O
cell	623	627	B-Cell
proliferation	628	641	O
,	641	642	O
escape	643	649	O
from	650	654	O
apoptosis	655	664	O
,	664	665	O
brain	666	671	B-Organ
invasion	672	680	O
,	680	681	O
and	682	685	O
aberrant	686	694	O
neoangiogenesis	695	710	O
.	710	711	O

Most	712	716	O
of	717	719	O
the	720	723	O
tumor	724	729	B-Pathological_formation
-	729	730	O
suppressive	730	741	O
properties	742	752	O
of	753	755	O
Pten	756	760	B-Gene_or_gene_product
are	761	764	O
dependent	765	774	O
on	775	777	O
its	778	781	O
lipid	782	787	B-Drug_or_compound
phosphatase	788	799	O
activity	800	808	O
,	808	809	O
which	810	815	O
inhibits	816	824	O
the	825	828	O
phosphatidylinositol	829	849	B-Gene_or_gene_product
-	849	850	I-Gene_or_gene_product
3	850	851	I-Gene_or_gene_product
'	851	852	I-Gene_or_gene_product
-	852	853	I-Gene_or_gene_product
kinase	853	859	I-Gene_or_gene_product
(	860	861	O
PI3K	861	865	B-Gene_or_gene_product
)	865	866	O
/	866	867	O
Akt	867	870	B-Gene_or_gene_product
signaling	871	880	O
pathway	881	888	O
through	889	896	O
dephosphorylation	897	914	O
of	915	917	O
phosphatidylinositol	918	938	B-Drug_or_compound
-	938	939	I-Drug_or_compound
(	939	940	I-Drug_or_compound
3	940	941	I-Drug_or_compound
,	941	942	I-Drug_or_compound
4	942	943	I-Drug_or_compound
,	943	944	I-Drug_or_compound
5	944	945	I-Drug_or_compound
)	945	946	I-Drug_or_compound
-	946	947	I-Drug_or_compound
triphosphate	947	959	I-Drug_or_compound
.	959	960	O

The	961	964	O
additional	965	975	O
function	976	984	O
of	985	987	O
Pten	988	992	B-Gene_or_gene_product
as	993	995	O
a	996	997	O
dual	998	1002	O
-	1002	1003	O
specificity	1003	1014	O
protein	1015	1022	O
phosphatase	1023	1034	O
may	1035	1038	O
also	1039	1043	O
play	1044	1048	O
a	1049	1050	O
role	1051	1055	O
in	1056	1058	O
glioma	1059	1065	B-Pathological_formation
pathogenesis	1066	1078	O
.	1078	1079	O

Besides	1080	1087	O
the	1088	1091	O
wealth	1092	1098	O
of	1099	1101	O
data	1102	1106	O
elucidating	1107	1118	O
the	1119	1122	O
functional	1123	1133	O
roles	1134	1139	O
of	1140	1142	O
Pten	1143	1147	B-Gene_or_gene_product
,	1147	1148	O
recent	1149	1155	O
studies	1156	1163	O
suggest	1164	1171	O
a	1172	1173	O
diagnostic	1174	1184	O
significance	1185	1197	O
of	1198	1200	O
PTEN	1201	1205	B-Gene_or_gene_product
gene	1206	1210	O
alterations	1211	1222	O
as	1223	1225	O
a	1226	1227	O
molecular	1228	1237	O
marker	1238	1244	O
for	1245	1248	O
poor	1249	1253	O
prognosis	1254	1263	O
in	1264	1266	O
anaplastic	1267	1277	O
astrocytomas	1278	1290	O
and	1291	1294	O
anaplastic	1295	1305	O
oligodendrogliomas	1306	1324	O
.	1324	1325	O

Furthermore	1326	1337	O
,	1337	1338	O
the	1339	1342	O
possibility	1343	1354	O
of	1355	1357	O
selective	1358	1367	O
targeting	1368	1377	O
of	1378	1380	O
PTEN	1381	1385	B-Gene_or_gene_product
mutant	1386	1392	O
tumor	1393	1398	O
cells	1399	1404	O
by	1405	1407	O
specific	1408	1416	O
pharmacologic	1417	1430	O
inhibitors	1431	1441	O
of	1442	1444	O
members	1445	1452	O
of	1453	1455	O
the	1456	1459	O
Pten	1460	1464	B-Gene_or_gene_product
/	1464	1465	O
PI3K	1465	1469	B-Gene_or_gene_product
/	1469	1470	O
Akt	1470	1473	B-Gene_or_gene_product
pathway	1474	1481	O
opens	1482	1487	O
up	1488	1490	O
new	1491	1494	O
perspectives	1495	1507	O
for	1508	1511	O
a	1512	1513	O
targeted	1514	1522	O
molecular	1523	1532	O
therapy	1533	1540	O
of	1541	1543	O
malignant	1544	1553	O
gliomas	1554	1561	B-Pathological_formation
.	1561	1562	O

